Home › Pure Autonomic Failure › NCT03312556
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Treatment of Supine Hypertension in Autonomic Failure With Continuous Positive Airway Pressure
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients with autonomic failure and with supine hypertension from all races Exclusion Criteria: * All medical students * Pregnant women * High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction) * History of serious allergies or asthma.
About the study
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.
What is being tested
- continuous positive airway pressure (CPAP) (device)
- Placebo (drug)
Sponsor: Vanderbilt University Medical Center · Participants: 12 · Started: Sep 21, 2017
Contact the study team
- Bonnie K Black, RN · Phone: 615-343-6862
- Luis E Okamoto, MD · Phone: (615) 936-6119
Official record on ClinicalTrials.gov — NCT03312556
Locations in the U.S.
| Tennessee | Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.